HCA Healthcare Third Quarter 2026 Earnings Call - HCA HEALTHCARE INC

Financial Performance:

• Adjusted diluted EPS increased approximately 4% year-over-year.
• Admissions grew 3% on a same-facility basis (equivalent admissions up 3.0%, ER visits +5.1%), while inpatient (-1.4%) and outpatient (-3.7%) surgeries declined.
• Uninsured volume grew to 10.5% of total equivalent admissions (from 8.5%), driven largely by a one-for-one migration from health insurance exchanges.
• A "pyramid shift" from exchanges to uninsured status negatively impacted adjusted EBITDA by approximately $400 million in the quarter.
• Recognized $50 million in incremental net benefits from Medicaid supplemental payments (primarily Virginia), bringing full-year 2026 expectations to $600–$800 million.
• Cost performance improved, with same-facility costs per equivalent admission (excluding state supplemental payments) essentially flat year-over-year and down 40 basis points sequentially.
• Capital expenditures totaled $1.36 billion; share repurchases were $3.0 billion; dividends paid were $165 million; operating cash flow was $4.5 billion.
• Debt-to-adjusted EBITDA leverage remains in the lower half of the target range.

Guidance and Future Outlook:

• Reaffirmed 2026 guidance, now expecting to land in the upper half of the previously stated ranges.
• Preliminary outlook for 2027 forecasts 2–3% volume growth, consistent with long-term targets.
• Anticipates 2027 adjusted EBITDA to be generally consistent with 2026 levels, assuming no material policy changes beyond H.R. 1.
• Expects $550–$650 million fewer Medicaid supplemental payment net benefits in 2027 due to the expiration of 2026 grandfathered state programs.
• Foresees fewer net losses in health insurance exchange coverage for 2027 compared to 2026, though payer mix pressure is expected to persist.
• Beyond 2027, management expects performance to align more closely with long-term growth targets driven by digital transformation, network development, and resiliency.

Business Segments and Product Lines:

• Elective Surgery: Facing headwinds from exchange coverage losses and affordability concerns; however, emergent surgical volumes remain strong.
• Ambulatory Network: Expanding to nearly 3,000 units through acquisitions of urgent care and ASCs; focusing on patient coordination and flow.
• Service Mix: Compensating for elective surgery declines with growth in neonatal, cardiac, trauma, and EMS traffic volumes.
• Medicaid Supplemental Programs: Recent Virginia program approval drove Q3 benefits; full-year 2026 guidance increased to reflect these one-time and recurring state payments.

Market and Competitive Landscape:

• Operating in roughly 43 U.S. markets, having intentionally pruned the portfolio over the last 7–8 years to focus on high-probability success.
• No plans for market exits; the company remains opportunistic for new acquisitions if they fit the execution model and are affordable.
• Gaining incremental market share in many regions through network expansion and capacity increases (inpatient occupancy near 75%).
• Navigating the Medicare Inpatient-Only List phase-out, with year one focusing on orthopedic procedures; migration to outpatient is partially offset by expanding ambulatory platforms.
• Commercial volume (excluding exchanges) grew 2.7%, outpacing the exchange decline of 19%, demonstrating core resilience.

Risks and Challenges:

• Payer Mix: Continued migration of patients from exchanges to uninsured status remains a significant negative driver for revenue per unit.
• Policy Uncertainty: H.R. 1 work requirements in Medicaid expansion states could impact 15–20% of Medicaid volume in those regions; budget-neutral 340B rules remain under watch.
• Elective Demand: Broader economic affordability and coverage dynamics continue to suppress elective surgical volumes, with no assumed seasonal tailwind in Q4 2026.
• Professional Fees: Rising costs (up 12% YoY, representing 24% of other operating expenses), driven primarily by radiology and anesthesiology.
• State Payments: Future reduction in Medicaid supplemental payments as 2026 grandfathered approvals expire.

Management Commentary and Tone:

• Tone was confident and disciplined, emphasizing the company's "staying power" despite a challenging federal policy environment.
• Management highlighted 22 consecutive quarters of volume growth as evidence of a resilient business model.
• Emphasized that cost resiliency is now a permanent, core component of operations rather than a one-time event.
• Expressed optimism regarding long-term strategic initiatives, including AI transformation and digital capabilities, to drive future value.
• Stressed that the company is well-positioned to end 2026 positively and navigate into 2027 with a balanced capital allocation strategy.

Analyst Questions and Answers:

• 2027 Growth Drivers: Management clarified that 2027 growth assumes a blend of organic demand (2–3%), continued cost savings from resiliency, and mitigated exchange headwinds.
• Surgical Trends: No specific recovery for elective surgery was forecasted for 2027; growth will be driven by diverse services (NICU, cardiac, trauma) compensating for surgical softness.
• Q4 Visibility: Management declined to size Q4 exchange performance or surgical pickup before Q4 results, noting seasonality and the Nov-Jan enrollment period will provide clearer data.
• 340B Impact: Viewed the proposed Medicare OPTS rule as potentially beneficial (budget-neutral reallocation), but not currently sized in guidance.
• Market Position: Reiterated no material changes to the geographic footprint; focus remains on optimizing the existing 43 markets and expanding ambulatory access.

Other Key Points:

• Resiliency Program: Defined across four pillars: revenue integrity, asset optimization (patient flow), variable costs (labor/supplies), and fixed costs.
• Capital Allocation: Share repurchase program expected to be nearly complete by year-end, subject to market conditions.
• Labor Trends: Q3 saw typical merit adjustment increases, yet overall expense efficiency improved due to state payments and operating leverage.
• Payer Relations: Management noted progress on 2027 contract cycling but remains concerned about payer attitudes; 2028 contracts are in early stages.
• Professional Fees: Identified as a persistent pressure point, though net revenue per unit growth helped offset these costs.